POSSIBILITIES OF COMBINATION TREATMENT FOR CHRONIC CERVICITIS

Objective. To assess whether tyloron (lavomax) may be used in the combination treatment of cervicitis caused by Chlamydia infection. Subjects and methods. The study enrolled 30 patients aged 18 to 45 years (mean age 26.2±1.2 years) with the clinical manifestations and verified diagnosis of urogenital chlamydiasis; according to the clinical and laboratory findings, they were divided into 2 groups: 1) 15 patients who took lavomax as part of combination therapy; 2) 15 patients who received standard antibacterial therapy for chlamydiasis. Results. The clinical symptoms observed before therapy and the signs of cervicitis during expanded colposcopy were absent in 93.3 and 80% of Groups 1 and 2 patients, respectively. Insignificant clinical symptoms were observed in 6.7 and 20% of Groups 1 and 2 patients, respectively. The levels of interferons (IFN) a and γ were substantially unchanged in Group 2 patients; Group 1 patients showed almost 1.5- and almost 3-fold increases in the concentrations of IFN-a and IFN-γ, respectively. Conclusion. The use of lavomax as part of combination therapy for cervicitis caused by Chlamydia infection results in a pronounced positive clinical effect and promotes more complete cessation of the clinical symptoms of urogenital chlamydiasis than the standard antibacterial therapy.

chronic cervicitis, chlamydiasis, tyrolon, interferon inductors